Merck Raises Vioxx, Arcoxia Guidance; Ex-U.S. Sales Spur Growth
Executive Summary
Merck is raising its 2004 sales guidance for its global COX-2 inhibitor business to the $2.8 bil.-$3 bil. range based on faster than expected growth for Vioxx and Arcoxia.
You may also be interested in...
COX-2 Class Is TARGET Of Critical Lancet Editorial
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs
COX-2 Class Is TARGET Of Critical Lancet Editorial
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs
Merck Sees Strong Cholesterol Market In ‘04; Zocor Growth, Profit From Zetia
Merck expects Zocor sales to remain in the $5 bil. range in 2004 despite generic erosion overseas and the introduction of new competitors in the cholesterol class